Scientific Congresses

Selected Data Presentations at Scientific Congresses

Explore below for information pertaining to recent scientific congresses related to gastroenterology. This is not intended to be a comprehensive resource of all congresses and congress materials across therapeutic and disease areas.

Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.

 

Upcoming & Past Conferences

  • Upcoming

  • Past

GASTROENTEROLOGY

Advances in Inflammatory Bowel Diseases (AIBD), 2022

December 5 - 7, 2022 | Link to Event
An all-encompassing event providing real-world clinical education, case studies and new evidence-based approaches in IBD management.

GASTROENTEROLOGY

Crohn's & Colitis Congress (CCC), 2023

January 19 - 21, 2023 | Link to Event
Premier conference for a multidisciplinary community of practitioners and researchers focusing on inflammatory bowel disease (IBD) by pairing best practices in clinical care with innovative research.

GASTROENTEROLOGY

American College of Gastroenterology (ACG), 2022

October 21 - 26, 2022 | Link to Event
Premier educational event for clinicians and the general public about digestive disorders and the latest trends in GI technology and therapeutics.

GASTROENTEROLOGY

Federation of Clinical Immunology Societies (FOCIS), 2022

June 21 - 24, 2022 | Link to Event
Annual meeting with a unique focus on translational immunology and interdisciplinary approaches to understanding disease and identifying new therapeutic approaches.

GASTROENTEROLOGY

Digestive Disease Week (DDW), 2022

May 21 - 24, 2022 | Link to Event
Global meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

  • An artificial intelligence–driven scoring system to measure histological disease activity in ulcerative colitis
  • High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study

Motegrity® (prucalopride)

  • A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation
  • Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age: a post hoc analysis of phase 3 and 4 clinical trials

Entyvio® (vedolizumab)

  • A Single-Cell Approach Reveals Immune Cell Dynamics in Inflammatory Bowel Disease (IBD) and Highlights Association of CD8 Intraepithelial Lymphocytes (IELs) With Response to Vedolizumab Treatment
  • A Single-Cell Approach Reveals Immune Cell Dynamics in Inflammatory Bowel Disease (IBD) and Highlights Association of CD8 Intraepithelial Lymphocytes (IELs) With Response to Vedolizumab Treatment
  • Effects of anti-integrin a4b7 on colon immune cells
  • Poster Mo1550 – Supplemental Material Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings From ROTARY Part A
  • Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings From ROTARY Part A
  • Early Versus Delayed Initiation of Vedolizumab in Ulcerative Colitis: Real World Treatment Response (RALEE)
  • Adverse Clinical Outcomes in Patients With Crohn’s Disease Receiving Different Sequences of First- and Second-Line Biologic Treatments: Findings From ROTARY
  • Uptake and Patterns of Influenza Vaccine Administration Among Patients With Inflammatory Bowel Disease: a Claims-Based Analysis
  • Early Modification of Inflammatory Burden Through Treatment With Vedolizumab or Adalimumab is Predictive of Long-Term Treatment Success in Patients With Ulcerative Colitis From the VARSITY Study
  • Identifying the Most Effective Treatment Algorithm for Therapies to Treat Moderate to Severe Ulcerative Colitis

GASTROENTEROLOGY

The American Association of Immunologists (AAI), 2022

May 6 - 10, 2022 | Link to Event
Annual meeting brings together leading immunology scientists from around the world to present their research in lectures and major symposia.

GASTROENTEROLOGY

Academy of Managed Care Pharmacy (AMCP), 2022

March 29 - April 1, 2022 | Link to Event
The largest assembly of pharmacy and health care professionals dedicated to the issues of managed care pharmacy offering immersive education sessions and keynote presentations.

Motegrity® (prucalopride)

  • Healthcare resource use before and after the initiation of prucalopride treatment: a real-world study in patients with constipation in the USA
  • Healthcare costs before and after the initiation of prucalopride treatment: a real-world study in patients with constipation in the USA

Gastroenterology

Inflammatory Bowel Disease Horizons (IBD Horizons), 2022

March 5, 2022 | Link to Event
Focused on the education related to diagnosis, management and advancement of IBD providing accredited symposia where access to IBD specialists and centers is limited.

Entyvio® (vedolizumab)

  • Adverse Clinical Outcomes in Patients With Crohn’s Disease Receiving Different Sequences of First- and Second-Line Biologic Treatments: Findings From ROTARY
  • Early Versus Delayed Initiation of Vedolizumab in Ulcerative Colitis: Real World Treatment Response (RALEE)

Gastroenterology

European Crohn's and Colitis Organization (ECCO), 2022

February 16 - 19, 2022 | Link to Event
Global congress focused on optimizing care for patients with IBD by offering sessions around basic science, traditional medication and clinical discussions.

  • Real-world characteristics and complications of patients with ulcerative colitis receiving conventional therapy in the public healthcare system in Brazil
  • Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study
  • Examining faecal incontinence and its impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a multi-country burden of illness study
  • High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study
  • An artificial intelligence–driven scoring system to measure histological disease activity in ulcerative colitis
  • Development and validation of a 13 item short version of the IBD self efficacy scale
  • The impact of seton use on clinical and patient-reported outcomes in Crohn’s disease perianal fistulas: findings from a systematic literature review

Entyvio® (vedolizumab)

  • Mucosal eosinophil abundance in non-inflamed colonic tissue predicts response to vedolizumab induction therapy in inflammatory bowel disease
  • Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment
  • A Single-Cell Approach Reveals Immune Cell Dynamics in Inflammatory Bowel Disease (IBD) and Highlights Association of CD8 Intraepithelial Lymphocytes (IELs) With Response to Vedolizumab Treatment
  • A Single-Cell Approach Reveals Immune Cell Dynamics in Inflammatory Bowel Disease (IBD) and Highlights Association of CD8 Intraepithelial Lymphocytes (IELs) With Response to Vedolizumab Treatment
  • Early Modification of Inflammatory Burden Through Treatment With Vedolizumab or Adalimumab is Predictive of Long-Term Treatment Success in Patients With Ulcerative Colitis From the VARSITY Study
  • Predictors of Pancreatitis Among Patients With Inflammatory Bowel Disease Treated With Vedolizumab: Observation From a Large Global Safety Database

Gastroenterology

Crohn's & Colitis Congress (CCC), 2022

January 20 - 22, 2022 | Link to Event
Premier conference for a multidisciplinary community of practitioners and researchers focusing on inflammatory bowel disease (IBD) by pairing best practices in clinical care with innovative research.

Entyvio® (vedolizumab)

  • Adverse Clinical Outcomes in Patients With Crohn’s Disease Receiving Different Sequences of First- and Second-Line Biologic Treatments: Findings From ROTARY
  • Adverse Clinical Outcomes in Patients With Ulcerative Colitis Receiving Different Sequences of First- and Second-Line Biologic Treatments: Findings From ROTARY
  • Early Versus Delayed Initiation of Vedolizumab in Ulcerative Colitis: Treatment Response in the Real World (RALEE)
  • Identifying the most effective treatment algorithm for therapies to treat moderate to severe ulcerative colitis

Gastroenterology

North American Society For Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN), 2021

December 12 - 18, 2021 | Link to Event
Annual forum for participants to learn about the latest advances in pediatric gastroenterology, hepatology and nutrition and to discuss current topics in clinical applications.

Gastroenterology

Advances in Inflammatory Bowel Diseases (AIBD), 2021

December 9 - 11, 2021 | Link to Event
An all-encompassing event providing real-world clinical education, case studies and new evidence-based approaches in IBD management.

  • Disparities in Diagnosis and Management of Patients with Crohn's Perianal Fistulas- Results of a US National Patient and Caregiver Survey

Entyvio® (vedolizumab)

  • Early Versus Later Use of Vedolizumab in IBD: Patient Characteristics and Treatment Patterns in the Real World (RALEE)

Gastroenterology

American College of Gastroenterology (ACG), 2021

October 22 - 27, 2021 | Link to Event
Premier educational event for clinicians and the general public about digestive disorders and the latest trends in GI technology and therapeutics.

  • Results of a US National Case-based Survey to Determine Future Educational Needs
  • Applying Machine Learning to Large Databases to Predict Nonresponse to Conventional Treatment in Patients With Crohn’s Disease
  • Results of a US national Survey

Motegrity® (prucalopride)

  • Healthcare resource use before and after the initiation of prucalopride treatment: a real-world study in patients with constipation in the USA
  • Healthcare costs before and after the initiation of prucalopride treatment: a real-world study in patients with constipation in the USA
  • Clinical outcomes before and after the initiation of prucalopride treatment: a real-world study in patients with constipation in the USA

Entyvio® (vedolizumab)

  • Costs for Treating Patients With Ulcerative Colitis With Vedolizumab or Adalimumab Based on Endoscopic Improvement Data From the VARSITY Trial
  • Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings From ROTARY Part A
  • Sequencing of Anti-TNF Agents and Vedolizumab in the Treatment of Crohn’s Disease
  • Supplement: Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings From ROTARY Part A
  • The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update
  • Use of Biologic Therapies With Different Mechanisms of Action in the First-Line Treatment of Crohn's Disease in the United States

Gastroenterology

European Crohn's and Colitis Organization (ECCO), 2021

July 2 - 3, 2021 | Link to Event
Global congress focused on optimizing care for patients with IBD by offering sessions around basic science, traditional medication and clinical discussions.

  • Treatment patterns of patients with perianal fistulizing Crohn’s disease from a US administrative claims database
  • Real-world treatment patterns and recurrence rates of rectovaginal fistulas in patients with Crohn's disease: a retrospective cohort database analysis
  • Development of a new patient-reported outcome measure for patients with complex cryptoglandular fistulas
  • Awareness, knowledge, and use of mesenchymal stem cells (MSCs) - a global survey among gastroenterologists and colorectal surgeons
  • Epidemiology and outcomes associated with local surgical and intersphincteric ligation procedures for complex cryptoglandular fistulas: a systematic literature review
  • Epidemiology and patient burden of rectovaginal and anovaginal fistulas in patients with Crohn's disease: a systematic review
  • An observational study to evaluate the burden of illness in patients with Crohn’s disease with and without perianal fistulas in the USA

Entyvio® (vedolizumab)

  • An Exploratory Analysis of the Impact of COVID-19 on Colonoscopy Procedures and New Biologic Treatment Initiation among Patients with Inflammatory Bowel Disease in the United States (Supplement)
  • Evolving Targets in Ulcerative Colitis: Defining Disease Clearance in the VARSITY Study
  • Use of biologic therapies with different mechanisms of action in the first-line treatment of Crohn's disease in the U.S.
  • Sequencing of Anti-TNF Agents and Gut-Selective Anti-Lymphocyte Trafficking Therapy in the Treatment of Crohn's Disease
  • Investigating Fatigue in Vedolizumab-Treated Patients With Ulcerative Colitis or Crohn's Disease From a Belgian Registry
  • Simplified rules to identify bio-naïve patients with Crohn's disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNF𝞪 therapies: analysis of EVOLVE study data
  • An Exploratory Analysis of the Impact of COVID-19 on Colonoscopy Procedures and New Biologic Treatment Initiation among Patients with Inflammatory Bowel Disease in the United States
  • Vedolizumab Maintenance Therapy Reduced Use of Corticosteroids in Patients with Crohn's Disease in the GEMINI 2 Trial
  • Payer Addressable Burden of Crohn's Disease in Patients Treated with Ustekinumab and Vedolizumab in the United States (Supplement)
  • Payer Addressable Burden of Crohn's Disease in Patients Treated with Ustekinumab and Vedolizumab in the United States
  • Assessment of Treatment Sequence and Real-world Outcomes in Patients with Ulcerative Colitis
  • Optimising Vedolizumab in Treatment Sequences for Crohn's Disease: Results From a Simulation Model Using Real-World Evidence

Gastroenterology

American Association for the Study of Liver Diseases (AASLD), 2021

June 23 - 26, 2021 | Link to Event
Global event for clinicians, associates, and scientists in the field of hepatology to share and discuss new developments in liver treatment and transplantation.

Gastroenterology

Digestive Disease Week (DDW), 2021

May 21 - 23, 2021 | Link to Event
Global meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

  • Impact on Caregivers of Adult Patients Receiving Parenteral Support for Intestinal Failure Associated with Short Bowel Syndrome: A Multinational, Non-interventional, Cross-Sectional Survey
  • Evaluating the Burden of Symptoms and Fecal Incontinence in Crohn's Disease With and Without Perianal Fistulas: An Observational Burden of Illness Study in US Patients
  • Impact of Crohn's Perianal Fistulas on Health-Related Quality of Life: An Observational Burden of Illness Study in US Patients
  • Symptoms, Comorbidities and Treatment Satisfaction in Adult Patients Receiving Parenteral Support for Intestinal Failure Associated with Short Bowel Syndrome

Gattex® (teduglutide)

  • Real-world effectiveness and safety of teduglutide in adult short bowel syndrome: a meta-analysis

Entyvio® (vedolizumab)

  • Biomarkers of extracellular matrix remodeling identify responders to vedolizumab therapy in subjects with ulcerative colitis in the GEMINI I study
  • Symptomatic Improvement with Vedolizumab Therapy for Crohn's Disease Stratified by Disease Activity and Prior Tumor Necrosis Factor Antagonist Failure: Post Hoc Analyses from the GEMINI 2 Trial (Supplement)
  • Symptomatic Improvement with Vedolizumab Therapy for Crohn's Disease Stratified by Disease Activity and Prior Tumor Necrosis Factor Antagonist Failure: Post Hoc Analyses from the GEMINI 2 Trial
  • Real-World Effectiveness of First-Line Biologics Vedolizumab in Crohn's Disease: Analysis of Higher Treatment Effect Subpopulation From the EVOLVE Study
  • Vedolizumab Rates of Mucosal Healing in Crohn's Disease: A Systematic Literature Review and Meta-Analysis of Real-World Data (Supplement)
  • Vedolizumab Rates of Mucosal Healing in Crohn's Disease: A Systematic Literature Review and Meta-Analysis of Real-World Data
  • Prognostic value of fecal calprotectin in patients with biologic-treated ulcerative colitis

Gastroenterology

Professional Society for Health Economics and Outcomes Research (ISPOR), 2021

May 17 - 20, 2021 | Link to Event
Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.

  • Evaluating Health-Related Quality of Life (HRQoL) in Patients With and Without Crohn's Perianal Fistulas (CPF) Using the EuroQol Five-Dimension (EQ-5D-5L) Questionnaire in a Real-World US Setting

Gastroenterology

Academy of Managed Care Pharmacy (AMCP), 2021

April 12 - 16, 2021 | Link to Event
The largest assembly of pharmacy and health care professionals dedicated to the issues of managed care pharmacy offering immersive education sessions and keynote presentations.

  • Economic Impact of Perianal Fistulizing Crohn's Disease in US Administrative Claims Data
  • Evaluating the Burden of Symptoms and Fecal Incontinence in Crohn's Disease With and Without Perianal Fistulas: An Observational Burden of Illness Study in US Patients
  • Impact of Crohn's Disease Perianal Fistulas on Patient's Work Productivity and Healthcare Resource Utilization

Gastroenterology

American Society for Parenteral and Enteral Nutrition (ASPEN), 2021

March 20 - 23, 2021 | Link to Event
Annual global conference for interdisciplinary, clinical nutrition leaders providing the latest in clinical nutrition research, education and products.

Gattex® (teduglutide)

  • A Prospective, Multicenter Registry for Patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF Registry): Interim Effectiveness Analysis of Teduglutide Treatment
  • A Prospective, Multicenter Registry for Patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF Registry): Interim Safety Analysis of Teduglutide Treatment